Stevanato Group S.p.A. (NYSE:STVN) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company.

A number of analysts have commented on the stock. Wolfe Research initiated coverage on shares of Stevanato Group in a report on Friday, December 13th. They issued an "outperform" rating and a $28.00 price objective for the company. Bank of America upped their price objective on Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a report on Friday, December 13th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. UBS Group reduced their price objective on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a report on Friday, March 7th. Finally, William Blair reaffirmed an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th.

Hedge Funds Weigh In On Stevanato Group

A number of hedge funds and other institutional investors have recently made changes to their positions in STVN. Natixis Advisors LLC grew its stake in shares of Stevanato Group by 20.3% in the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company's stock valued at $1,027,000 after purchasing an additional 8,669 shares during the last quarter. Raymond James Trust N.A. lifted its holdings in shares of Stevanato Group by 22.6% in the 3rd quarter. Raymond James Trust N.A. now owns 12,556 shares of the company's stock valued at $251,000 after buying an additional 2,317 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Stevanato Group by 16.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 294,235 shares of the company's stock valued at $5,885,000 after buying an additional 42,629 shares during the period. Hardy Reed LLC grew its holdings in Stevanato Group by 8.2% during the third quarter. Hardy Reed LLC now owns 11,077 shares of the company's stock worth $222,000 after acquiring an additional 840 shares during the period. Finally, Glenmede Trust Co. NA lifted its holdings in Stevanato Group by 12.7% in the third quarter. Glenmede Trust Co. NA now owns 35,941 shares of the company's stock valued at $719,000 after acquiring an additional 4,050 shares during the period.

Remove Ads

Stevanato Group Stock Performance

Shares of Stevanato Group stock traded down €0.79 ($0.85) during trading on Friday, hitting €21.56 ($23.18). 10,571 shares of the company's stock were exchanged, compared to its average volume of 341,550. The stock has a market capitalization of $6.53 billion, a price-to-earnings ratio of 45.87, a PEG ratio of 7.18 and a beta of 0.60. The business has a 50-day simple moving average of €21.04 and a 200-day simple moving average of €20.59. Stevanato Group has a 52-week low of €16.56 ($17.81) and a 52-week high of €33.49 ($36.01). The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting the consensus estimate of €0.20 ($0.22). The firm had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. On average, research analysts forecast that Stevanato Group will post 0.5 EPS for the current year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.